Investigational drug · Phase 3
Budigalimab
Also called: ABBV-181
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hepatocellular Carcinoma, Non Small Cell Lung Carcinoma, c-MET.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
27
Any phase or sponsor naming "Budigalimab"
First trial start
2023
Sep 21, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Budigalimab", any sponsor or status.
- Phase 121
Conditions studied
As listed on its trial records.
- Hepatocellular Carcinoma
- Non Small Cell Lung Carcinoma
- c-MET
- Urothelial Carcinoma
- Non-Small Cell Lung Cancer
- Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Esophageal Adenocarcinoma
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Bladder and urothelial cancer · Liver cancer (hepatocellular carcinoma) · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Budigalimab" as an intervention, largest first.
AbbVieAbbVie (ABBV)
NCT05005403 · 694 participants (planned) · Start Nov 1, 2021 · Primary completion Jul 2027
Drug: Azirkitug; Budigalimab and 2 more · For: Non-Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Micro Satellite Stable Colorectal Cancer and 4 more
Sites: Duarte, California; Irvine, California; Los Angeles, California · 48 sites in all
- Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid TumorsPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT03821935 · 364 participants · Start Feb 21, 2019 · Primary completion Jun 2027
Drug: Livmoniplimab; Budigalimab · For: Advanced Solid Tumors Cancer
Sites: Springdale, Arkansas; Duarte, California; Irvine, California · 64 sites in all
AbbVieAbbVie (ABBV)
NCT05599984 · 288 participants · Start Dec 5, 2022 · Primary completion Nov 2027
Drug: ABBV-706; Cisplatin and 2 more · For: Advanced Solid Tumors
Sites: Gilbert, Arizona; Duarte, California; Irvine, California · 66 sites in all
AbbVieAbbVie (ABBV)
NCT06772623 · 252 participants (planned) · Start Mar 6, 2025 · Primary completion Nov 2027
Drug: Telisotuzumab Adizutecan; Budigalimab and 5 more · For: Non Small Cell Lung Carcinoma; c-MET
Sites: Phoenix, Arizona; Fullerton, California; Oxnard, California · 131 sites in all
AbbVieAbbVie (ABBV)
NCT07241039 · 220 participants (planned) · Start Nov 20, 2025 · Primary completion Apr 2029
Drug: ABBV-711; Budigalimab · For: Advanced Squamous Tumors
Sites: Duarte, California; Irvine, California; Chicago, Illinois · 13 sites in all
- A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT06628310 · 185 participants · Start Dec 13, 2024 · Primary completion Oct 2030
Drug: Telisotuzumab Adizutecan; Budigalimab and 3 more · For: Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma
Sites: Duarte, California; Irvine, California; Santa Monica, California · 49 sites in all
AbbVieAbbVie (ABBV)
NCT03000257 · 182 participants · Start Dec 14, 2016 · Primary completion Mar 29, 2022
Drug: Venetoclax; Rovalpituzumab Tesirine and 1 more · For: Advanced Solid Tumors
Sites: La Jolla, California; Chicago, Illinois; Huntersville, North Carolina · 26 sites in all
- Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Pivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT06236438 · 167 participants · Start Apr 10, 2024 · Primary completion Oct 2031
Drug: Livmoniplimab; Budigalimab and 5 more · For: Non-Small Cell Lung Cancer
Sites: La Jolla, California; Pembroke Pines, Florida; Winter Haven, Florida · 61 sites in all
AbbVieAbbVie (ABBV)
NCT06032546 · 163 participants · Start Oct 12, 2023 · Primary completion Sep 22, 2025
Drug: Budigalimab; Placebo for Budigalimab and 3 more · For: Human Immuno-deficiency Virus (HIV) Disease
Sites: Birmingham, Alabama; Bakersfield, California; Beverly Hills, California · 80 sites in all
- A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid TumorsActive, not recruiting
AbbVieAbbVie (ABBV)
NCT02988960 · 163 participants · Start Feb 22, 2017 · Primary completion Sep 2026
Drug: ABBV-927; ABBV-927 and 1 more · For: Advanced Solid Tumors Cancer
Sites: Los Angeles, California; Chicago, Illinois; Boston, Massachusetts · 22 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Phase 1 study of OX40 agonist ABBV-368 as monotherapy or in combination with budigalimab in advanced solid tumors.
Oliva M, Powderly J, Le Tourneau C, et al. · Future Oncol 2026
- Safety, Pharmacokinetics, and Pharmacodynamics of Single-Dose Programmed Cell Death Protein 1 Inhibitor, Budigalimab, in People With HIV-1 With Antiretroviral Therapy-Suppressed Viral Load.
Vaidya TR, Geib T, Lalezari JP, et al. · J Infect Dis 2026
- Budigalimab: a viable option for patients with advanced solid tumors.
Mogenet A, Greillier L · Expert Opin Investig Drugs 2026
- Phase 1b study of ABBV-368, tilsotolimod, budigalimab, and nab-paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Daste A, Le X, Makkouk A, et al. · J Immunother Cancer 2026
- Analytical treatment interruption as a tool in the evaluation of immune-mediated interventions for long-term antiretroviral-free control of HIV-1 among people with HIV.
Pires Dos Santos AG, Abunimeh M, Mothe B, et al. · Contemp Clin Trials 2026
- Therapeutic Applications and Target Strategies of Antibody-Drug Conjugates in Ovarian Cancer.
Liu Q, Zhou R, He T, et al. · Iran J Pharm Res 2025
Also in development for Hepatocellular Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- PF-08634404SSGJ-707Phase 312 trials
Pfizer · Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC)
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AbbVie.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.